Low Molecular Heparin Combined Danhong Injection In The Early Application Of Portal Hypertension Splenectomy

Objective: Portal hypertension(portal hypertension PHT)as decompensated cirrhosis prominent clinical manifestationsOften accumulated many organs,symptoms may occur mainly pathological enlargement of the spleen,with or without hypersplenism,dangerous upper gastrointestinal bleeding,a series of clinical manifestations of hepatic encephalopathy,hepatorenal syndrome,liver and lung syndrome.In the treatment of decompensated cirrhosis,primarily treatment of complications(mainly esophageal-gastric varices).However,portal vein thrombosis reduces the prognosis and quality of life of patients.Portal vein thrombosis is a common complication of cirrhosis and portal hypertension after splenectomy,especially prevalent in the shunt,devascularization,liver transplantation,therefore,for the development of portal vein thrombosis early prevention,early detection and early treatment the scheme is very important.In this study,we summarized and analyzed in our department the past two years by making portal hypertension splenectomy low molecular heparin and Danhong injection clinical effect of early postoperative in for future use of the drug after clinical significance.Methods: Patients collected from February 2014 to December 2015 in the Second Hospital of Hebei Medical University,Hepatobiliary Surgery Hospital from cirrhosis complicated with portal hypertension splenectomy combined with pericardial blood vessel surgery patients off,and there are cases of complete data a total of 106 cases,divided experimental group and control group: the test group of 49 patients,including 30 males and 19 females,aged 30-66 years(37 ± 10.35 years);the control group 57 cases,including 35 males and 22 females,aged 30-70 years(45 ± 11.46 years),two groups of patients after surgery three days since the disease was stable,hemodynamic stability,peritoneal fluid drainage greater volatility does not appear,the drainage of fluid color red gradual transition to light bloody showed no active bleeding,no liver failure(including serum total bilirubin,alanine and aspartate aminotransferase were increased,massive ascites,hepatic encephalopathy,etc.)related to performance.Three days after the operation daily review of blood clotting,liver function,electrolytes,and then check once every three days blood clotting,liver function,electrolytes.Start on the first three days,the experimental group began to use anticoagulation therapy scheme: the Danhong injection(10ml)was added 5% glucose injection 100 ml slow intravenous input,20ml/d,treatment for 7d,subcutaneous low molecular heparin injection(0.6ml: 6000 AxaIU,Hangzhou Jiuyuan gene Engineering Co.,Ltd.)6000IU/d,treatment for 7d,closely monitor patients during treatment partial thromboplastin time.The control group applied low molecular heparin subcutaneous injection(0.6ml: 6000 AxaIU,Hangzhou Jiuyuan Gene Engineering Co.,Ltd.)6000IU/d,treatment for 7d.Record and observe the following data: Preoperative general condition of patients,etiology,liver function,prothrombin time,plasma D-dimer,postoperative platelet count,prothrombin time,and 12 weeks after surgery,portal vein thrombosis rate,using the X2 test and t-test statistical methods for the two groups were analyzed.Results: Two groups of patients in the preoperative observation data,in general(gender,age,PLT count,portal vein diameter,splenic vein diameter),etiology,liver function Child-Pugh classification,PT,plasma D-dimer no statistical difference significance(P>0.05),after close follow-up of 12 weeks,12 weeks after the test group of portal vein thrombosis in 1 case,accounting for 2% in the control group after 12 weeks of portal vein thrombosis in 7 cases,accounting for 14%,two groups of comparison,difference have statistical significance(X2=3.960,P=0.047),treatment group is better than the control group.Conclusion: Portal vein thrombosis is cirrhosis and portal hypertension splenectomy complications,low molecular heparin combined Danhong injection can effectively reduce cirrhosis and portal hypertension splenectomy portal vein thrombosis rates,but long-term efficacy analysis,also we need to study and follow-up of large amounts of samples for longer periods.